Paul Workman
Title
Cited by
Cited by
Year
Guidelines for the welfare and use of animals in cancer research
P Workman, EO Aboagye, F Balkwill, A Balmain, G Bruder, DJ Chaplin, ...
British journal of cancer 102 (11), 1555-1577, 2010
10692010
Hsp90 molecular chaperone inhibitors: are we there yet?
L Neckers, P Workman
Clinical cancer research 18 (1), 64-76, 2012
8552012
Combinatorial drug therapy for cancer in the post-genomic era
B Al-Lazikani, U Banerji, P Workman
Nature biotechnology 30 (7), 679-692, 2012
7352012
Animals in Experimental Neoplasia
P Workman
7251998
The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective …
AJ Folkes, K Ahmadi, WK Alderton, S Alix, SJ Baker, G Box, ...
Journal of medicinal chemistry 51 (18), 5522-5532, 2008
7162008
HSP90 as a new therapeutic target for cancer therapy: the story unfolds
A Maloney, P Workman
Expert opinion on biological therapy 2 (1), 3-24, 2002
6662002
Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises
TA Yap, MD Garrett, MI Walton, F Raynaud, JS de Bono, P Workman
Current opinion in pharmacology 8 (4), 393-412, 2008
5692008
Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress
P Workman, F Burrows, LEN Neckers, N Rosen
Annals of the New York Academy of Sciences 1113 (1), 202-216, 2007
5462007
Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1
B Panaretou, G Siligardi, P Meyer, A Maloney, JK Sullivan, S Singh, ...
Molecular cell 10 (6), 1307-1318, 2002
5452002
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations
MO Leach, KM Brindle, JL Evelhoch, JR Griffiths, MR Horsman, A Jackson, ...
British journal of cancer 92 (9), 1599-1610, 2005
5402005
Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies
U Banerji, A O'Donnell, M Scurr, S Pacey, S Stapleton, Y Asad, ...
Journal of Clinical Oncology 23 (18), 4152-4161, 2005
5242005
The promise and peril of chemical probes
CH Arrowsmith, JE Audia, C Austin, J Baell, J Bennett, J Blagg, C Bountra, ...
Nature chemical biology 11 (8), 536-541, 2015
5032015
Discovery of small molecule cancer drugs: successes, challenges and opportunities
S Hoelder, PA Clarke, P Workman
Molecular oncology 6 (2), 155-176, 2012
4752012
The Hsp90 molecular chaperone: an open and shut case for treatment
LH Pearl, C Prodromou, P Workman
Biochemical Journal 410 (3), 439-453, 2008
4642008
Imaging biomarker roadmap for cancer studies
JPB O'Connor, EO Aboagye, JE Adams, HJWL Aerts, SF Barrington, ...
Nature reviews Clinical oncology 14 (3), 169-186, 2017
4572017
NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis
SA Eccles, A Massey, FI Raynaud, SY Sharp, G Box, M Valenti, ...
Cancer research 68 (8), 2850-2860, 2008
4532008
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
G Vlachogiannis, S Hedayat, A Vatsiou, Y Jamin, J Fernández-Mateos, ...
Science 359 (6378), 920-926, 2018
4362018
New approaches to molecular cancer therapeutics
I Collins, P Workman
Nature Chemical Biology 2 (12), 689-700, 2006
4292006
DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90
LR Kelland, SY Sharp, PM Rogers, TG Myers, P Workman
Journal of the National Cancer Institute 91 (22), 1940-1949, 1999
4201999
4, 5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer
PA Brough, W Aherne, X Barril, J Borgognoni, K Boxall, JE Cansfield, ...
Journal of medicinal chemistry 51 (2), 196-218, 2008
4172008
The system can't perform the operation now. Try again later.
Articles 1–20